top of page


At Oxion Biologics, our aim is to enter clinical development with CTA/IND and a first-in-human phase 1 with our lead asset, OX118, a potential best-in-class monoclonal antibody targeting OX40 Ligand. during 2024. In addition, parallel development is being done for multiple indications where OX118 shows promise of delivering best-in-class performance in the field of autoimmunity and immune-mediated diseases. 

Our next-generation portfolio is based on novel antibody fragment-derived constructs displaying high-affinity binding to OX40L and/or other synergistic targets, which we intend to develop as followups to OX118. These assets are intended to break new ground as first-in-class treatments for respective, hitherto undisclosed indications in the autoimmune and immune-mediated disease fields. 

Pipeline 23Q3 (1).png
bottom of page